Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.40 |
| ▸ | FASN | P49327 | 3/20 | 0.38 |
| ▸ | CHRM5 | P08912 | 10/20 | 0.36 |
| ▸ | PRKDC | P78527 | 2/20 | 0.35 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.35 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.34 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.34 |
| ▸ | PIK3CD | O00329 | 1/20 | 0.34 |
| ▸ | KEAP1 | Q14145 | 1/20 | 0.33 |
| ▸ | DYRK1A | Q13627 | 1/20 | 0.33 |
| ▸ | AXL | P30530 | 1/20 | 0.33 |
| ▸ | FLT3 | P36888 | 1/20 | 0.33 |
| ▸ | MERTK | Q12866 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24231726 | 0.80 | CHRM5 (0.36) | FASNCHRM5KCNH2 | |
| SCHEMBL25229589 | 0.78 | GPR119 (0.46) | L3MBTL1FASN | |
| SCHEMBL24231535 | 0.77 | SCN9A (0.35) | FASNAXLFLT3MERTK | |
| SCHEMBL26359073 | 0.76 | KEAP1 (0.34) | FASNKCNH2KEAP1DYRK1AAXL | |
| SCHEMBL11985799 | 0.76 | L3MBTL1 (0.44) | L3MBTL1PRKDCKCNH2CYP3A4KEAP1 | |
| SCHEMBL25231654 | 0.76 | CHRM5 (0.58) | CHRM5KCNH2CYP3A4CYP2D6 | |
| SCHEMBL25280620 | 0.76 | CHRM5 (0.70) | CHRM5CYP3A4CYP2D6 | |
| SCHEMBL30456448 | 0.76 | CHRM5 (0.57) | CHRM5CYP3A4CYP2D6 | |
| SCHEMBL25227448 | 0.76 | CHRM5 (0.57) | CHRM5CYP3A4CYP2D6 | |
| SCHEMBL25276383 | 0.76 | CHRM5 (0.70) | CHRM5KCNH2CYP3A4CYP2D6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230303563-A1 | MULTI-CYCLIC IRAK AND FLT3 INHIBITING COMPOUNDS AND USES THEREOF | CHILDREN'S HOSPITAL MEDICAL CENTER | 2023-09-28 | — | — | US | disclosed |
| EP-2114941-B1 | BICYCLIC HETEROCYCLIC COMPOUNDS AS FGFR INHIBITORS | ASTEX THERAPEUTICS LTD (GB) | 2015-03-25 | — | — | EP | disclosed |
| EP-2114941-B1 | BICYCLIC HETEROCYCLIC COMPOUNDS AS FGFR INHIBITORS | ASTEX THERAPEUTICS LTD (GB) | 2015-03-25 | — | — | EP | disclosed |
| US-8895745-B2 | Bicyclic heterocyclic compounds as FGFR inhibitors | ASTEX THERAPEUTICS LIMITED (GB) | 2014-11-25 | — | — | US | disclosed |
| US-8895745-B2 | Bicyclic heterocyclic compounds as FGFR inhibitors | ASTEX THERAPEUTICS LIMITED (GB) | 2014-11-25 | — | — | US | disclosed |
| US-8895745-B2 | Bicyclic heterocyclic compounds as FGFR inhibitors | ASTEX THERAPEUTICS LIMITED (GB) | 2014-11-25 | — | — | US | disclosed |
| US-20100120761-A1 | Bicyclic Heterocyclic Compounds as FGFR Inhibitors | ASTEX THERAPEUTICS LIMITED (GB) | 2010-05-13 | — | — | US | disclosed |
| US-20100120761-A1 | Bicyclic Heterocyclic Compounds as FGFR Inhibitors | ASTEX THERAPEUTICS LIMITED (GB) | 2010-05-13 | — | — | US | disclosed |
| US-20100120761-A1 | Bicyclic Heterocyclic Compounds as FGFR Inhibitors | ASTEX THERAPEUTICS LIMITED (GB) | 2010-05-13 | — | — | US | disclosed |
| EP-2114941-A1 | BICYCLIC HETEROCYCLIC COMPOUNDS AS FGFR INHIBITORS | Astex Therapeutics Limited (GB) | 2009-11-11 | — | — | EP | disclosed |
| WO-2008078091-A1 | BICYCLIC HETEROCYCLIC COMPOUNDS AS FGFR INHIBITORS | ASTEX THERAPEUTICS LIMITED (GB) | 2008-07-03 | — | — | WO | disclosed |
| WO-2008078091-A1 | BICYCLIC HETEROCYCLIC COMPOUNDS AS FGFR INHIBITORS | ASTEX THERAPEUTICS LIMITED (GB) | 2008-07-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230303563-A1 | MULTI-CYCLIC IRAK AND FLT3 INHIBITING COMPOUNDS AND USES THEREOF | FLT3, IRAK2, IRAK3 | L3MBTL1 1094/4885FASN 4049/4885CHRM5 2938/4885 |
| US-20100120761-A1 | Bicyclic Heterocyclic Compounds as FGFR Inhibitors | FGFR3, FGFR1, FGFR2 | L3MBTL1 3324/4885FASN 1048/4885CHRM5 4852/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.